Biohaven logo
Biohaven
BHVN | NYSE
Chart Builder DCF Calculator
$13.80
-$0.02 (-0.14%)
At close: Nov 16, 2026, 4:00 PM ET
$13.90
+$0.10 (+0.72%)
After-hours: Nov 16, 2026, 6:54 PM ET

Biohaven Company Profile

Company profile explained

Company Profile

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Key Executives

Name Position
Vladimir Coric Chairman & Chief Executive Officer
John McGill Chief Technology Officer
Matthew Buten Chief Financial Officer
Warren Volles General Counsel & Chief Legal Officer
Bruce D. Car DACVP Chief Innovation Officer
Clifford Bechtold President, GM of Biohaven Ireland & Chief Compliance Officer
Deb Young Senior Director of Regulatory Affairs & Operations
George C. Clark Vice President & Chief Accounting Officer
Jennifer Porcelli Vice President of Investor Relations
Kimberly Gentile Senior Vice President of Clinical Operations

Latest SEC Filings

Date Type Title
Oct 29, 2026 8-K Current Report
Oct 29, 2026 10-Q Quarterly Report
Oct 22, 2026 8-K Current Report
Oct 15, 2026 8-K Current Report
Sep 17, 2026 4 Filing
Sep 10, 2026 8-K Current Report
Aug 26, 2026 8-K Current Report
Aug 14, 2026 3 Filing
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 10, 2026 8-K Current Report
View All SEC Filings ➞
Biohaven
Biohaven logo
Country United States
IPO Date Sep 23, 2022
Industry Biotechnology
Sector Healthcare
Employees 274
CEO Vladimir Coric

Contact Details

215 Church Street New Haven, Connecticut 06510 United States

Stock Details

Ticker Symbol BHVN
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001935979
CUSIP Number G1110E107
ISIN Number VGG1110E1079
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.